Please assess the completion status of the following clinical trial:

Trial Title: Study of Preoperative Boost Radiotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Women with a biopsy proven diagnosis of ductal carcinoma in situ or invasive carcinoma of the breast. Biopsy tissue (either slides or block) from outside institutions will be reviewed to confirm diagnosis.~2. Breast preservation candidates (no prior breast or nodal radiotherapy, no imaging evidence of multicentric disease preventing resection through a single incision, no pregnant women, and no comorbid conditions precluding surgery)~3. cTis-T3 cancer judged to benefit (by treating radiation oncologist) from a tumor bed boost~4. Women of child-bearing potential must consent to use adequate contraception during the course of the study: (1) surgical sterilization (such as a tubal ligation or hysterectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD). Contraceptive measures such as Plan B (TM), sold for emergency use after unprotected sex, are not acceptable methods for routine use.~5. White blood cell (WBC) \> 3000, Hgb \> 10, platelets \>100000 within 30 days of consent~6. Eligible for contrasted magnetic resonance imaging( MRI) on initial evaluation with glomerular filtration rate (GFR) ≥ 60 ml/min. A diagnostic MRI ordered within 60 days of diagnosis will be considered an acceptable alternative and will not be repeated.~7. Outside breast imaging will be reviewed at Duke to confirm that findings are consistent with trial eligibility~Exclusion Criteria:~1. Breast implant in the breast to be treated (contralateral breast implant is acceptable)~2. Medical conditions that may increase risk for poor cosmetic outcome (i.e. Lupus, rheumatoid arthritis, scleroderma)~3. Subjects unable to receive study treatment planning secondary to body habitus or inability to lie flat on the stomach for at least 1 hour~4. Positive serum pregnancy test~5. Insufficient breast imaging to judge clinical stage~6. Subjects without placement of a biopsy clip at the diagnostic procedure who are unwilling to undergo clip placement.~7. Subjects in whom treatment planning constraints cannot be met

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Single arm 7 Gray (Gy) fraction of radiotherapy (Type: EXPERIMENTAL): All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).